Glaucoma Today: Genetics, New Treatments, and Emerging Insights

 Glaucoma Today: Genetics, New Treatments, and Emerging Insights

Glaucoma is one of the leading causes of irreversible vision loss worldwide — yet it often progresses silently, without pain or obvious symptoms. Many people are surprised to learn how much is changing in the way we understand and manage this condition, from genetics and laser treatments to artificial intelligence and nutrition research.

Glaucoma Genetic? What the Science Actually Says

One of the most common questions patients ask is: glaucoma inherited?

The answer is: partly — and the detail matters.

Glaucoma is not one disease but a family of conditions, each with its own genetic pattern. In younger patients diagnosed before age 40, there are often identifiable gene mutations at play — most notably in genes called MYOC and  CYP1B1 — which can be passed from parent to child with a 50% probability.

For the far more common adult-onset form, the picture is more complex. Large-scale genome-wide studies have now identified over 260 independent genetic risk locations, each contributing a small increase in risk. No single gene determines your fate. However, having a first-degree relative with glaucoma raises your personal risk substantially — estimates suggest up to nine times higher than the general population.

Ethnicity also plays a role. African and African-Caribbean populations face significantly higher rates of primary open-angle glaucoma, while people of East Asian descent have higher rates of angle-closure glaucoma.

What this means in practice: If glaucoma runs in your family, tell your eye doctor. Regular screening from your 40s onward is the most effective step you can take. Genetic testing is currently most useful for early-onset cases, not routine adult screening.

First-Line Treatment Is Evolving: The Case for SLT Laser

For decades, glaucoma treatment typically began with daily eye drops to lower intraocular pressure. That remains common — but a growing body of clinical evidence is shifting practice toward a different first step: a procedure called Selective Laser Trabeculoplasty, or SLT.

SLT works by applying a low-energy laser to the eye’s internal drainage tissue, prompting it to function more efficiently and reduce pressure naturally. The procedure takes around five minutes, causes no structural damage, and can be repeated if needed years later.

The evidence behind this shift is substantial. The landmark LiGHT trial — a six-year study led by Moorfields Eye Hospital in London — found that glaucoma progressed 29% more slowly in patients who started with SLT compared to those who began with eye drops. Around 70% of SLT-treated patients remained medication- and surgery-free at six years. These results, presented at the American Academy of Ophthalmology in 2024, are reshaping clinical guidelines across the UK, Europe, and increasingly the US.

Key advantages of SLT as a first-line option include:

No need for daily medication

Better adherence compared to drop-based therapy

Effective pressure control from early in the disease

Repeatable if pressure rises again over time

SLT is most effective for primary open-angle glaucoma and ocular hypertension. Speak with your specialist about whether it is appropriate for your situation.

AI in Glaucoma: Seeing What We Might Miss

The core challenge in glaucoma has always been timing. By the time most people notice something is wrong, significant and irreversible optic nerve damage has often already occurred. The nerve has no pain receptors, and peripheral vision — the first to be affected — is easy to compensate for without realising it.

Artificial intelligence is changing what’s detectable, and when. AI systems trained on millions of retinal images can now identify structural changes in the optic nerve that are nearly invisible to the human eye, even to experienced clinicians reviewing the same scan.

AI tools are also being used to analyse patterns in visual field tests over time — identifying whether a patient’s condition is stable or quietly advancing, and flagging those who may need earlier treatment adjustments. This kind of consistent, longitudinal pattern recognition across large datasets is where machine intelligence has a genuine clinical advantage.

These tools are beginning to appear in specialist clinics and are expected to become part of routine eye care within the next decade.

A New Frontier: Vitamin B3 (Nicotinamide) and the Metabolism of Glaucoma

One of the most unexpected developments in recent glaucoma research involves a simple, widely available vitamin. Nicotinamide — a form of vitamin B3 — has shown striking protective effects in animal models, and early human trials are generating real scientific interest.

The biological rationale is solid. Retinal ganglion cells — the neurons that glaucoma progressively destroys — are extraordinarily energy-demanding. As we age, levels of a key cellular energy molecule called NAD+ decline in the retina. When these cells are already under pressure from elevated intraocular pressure, reduced NAD+ may accelerate their degeneration. Nicotinamide is a precursor that helps restore NAD+ levels.

Two proof-of-concept human trials have produced encouraging early results:

A crossover trial in Melbourne (57 participants) found measurable improvements in inner retinal function with nicotinamide supplementation

A phase 2 trial in New York (32 participants) found significant short-term improvement in visual field performance

Supporting these findings, researchers at the CHU d’Angers in France measured significantly lower nicotinamide levels in the aqueous humor of glaucoma patients compared to healthy controls — providing direct biochemical evidence for the link.

Important context: These are small, short-term trials. The doses used — 3 grams per day, roughly 150 times the standard daily intake — are not comparable to ordinary supplementation. Two participants in these trials developed drug-induced liver injury. The American Glaucoma Society and the American Academy of Ophthalmology have issued guidance advising against self-supplementing at these doses outside of a clinical trial.

Larger, longer-term trials are currently underway in the US, UK, Sweden, Australia, and other countries, with results expected before 2027.

What makes this research genuinely exciting is that nicotinamide represents a fundamentally different approach: rather than targeting intraocular pressure — the focus of virtually every existing treatment — it aims to make nerve cells more resilient to damage. If confirmed in large trials, it would be the first neuroprotective therapy for glaucoma, a long-sought goal in the field.

Looking Ahead

Glaucoma care is entering a new era. Genetics is helping us identify who is most at risk. SLT laser is simplifying and strengthening first-line treatment. AI is enhancing early detection and monitoring. And nutritional research is opening entirely new therapeutic directions.

While glaucoma cannot yet be cured, we are getting better at detecting it earlier, treating it more effectively, and understanding its underlying biology.

If you have a family history of glaucoma or concerns about your eye health, regular screening remains the most important step you can take.

Medical Disclaimer

This article is intended for general informational and educational purposes only. It does not constitute medical advice and should not replace consultation with a qualified eye care professional. Treatment options, screening recommendations, and research findings vary by individual circumstance and may differ from current guidelines in your region. Regarding nicotinamide supplementation: doses referenced in clinical trials are substantially above standard dietary intake and have been associated with serious adverse events including drug-induced liver injury. Do not self-supplement at high doses without medical supervision. If you have concerns about your eye health, please consult a licensed healthcare provider.